Australia - English - Department of Health (Therapeutic Goods Administration)

abbott australasia pty ltd diagnostic division - 48316 - hepatitis b virus surface total antibody ivd, kit, chemiluminescent immunoassay - the architect anti-hbs assay is a chemiluminescent microparticle immunoassay (cmia) for the quantitative determination of antibody to hepatitis b surface antigen (anti-hbs) in clinical specimens. a chemiluminescent microparticle immunoassay (cmia) for the quantitative determination of antibody to hepatitis b surface antigen (anti-hbs) in clinical specimens.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbott australasia pty ltd diagnostic division - 48366 - hepatitis c virus total antibody ivd, kit, chemiluminescent assay - the architect anti-hcv assay is a chemiluminescent microparticle immunoassay (cmia) for the qualitative detection of antibody to hepatitis c virus (anti-hcv) in human serum and plasma including specimens collected post-mortem (non-heart-beating). the architect anti-hcv assay is intended to be used as an aid in the diagnosis of hepatitis c infection and as a screening test to prevent transmission of hepatitis c virus (hcv) to recipients of blood, blood components, cells, tissue and organs.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbott australasia pty ltd diagnostic division - 49713 - cytomegalovirus (cmv) immunoglobulin g (igg) antibody ivd, kit, chemiluminescent immunoassay - a chemiluminescent microparticle immunoassay for the qualitative detection and semi-quantitative determination of igg antibodies to cytomegalovirus in clinical specimens. a chemiluminescent microparticle immunoassay for the determination of igg antibodies to cytomegalovirus in clinical specimens.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbott australasia pty ltd diagnostic division - 48321 - hepatitis b virus surface antigen ivd, kit, chemiluminescent immunoassay - a chemiluminescent microparticle(cmia)assay for the qualitative detection of hepatitis b surface antigen in human clinical specimens. the architect hbsag qualitative ii assay is a chemiluminescent microparticle immunoassay (cmia) for the qualitative detection of hepatitis b surface antigen (hbsag) in human serum and plasma including specimens collected up to 24 hours post-mortem (non-heart-beating).

Australia - English - Department of Health (Therapeutic Goods Administration)

abbott australasia pty ltd diagnostic division - 48321 - hepatitis b virus surface antigen ivd, kit, chemiluminescent immunoassay - a chemiluminescent microparticle(cmia) assay for the confirmation of the presence of hbsag in clinical specimens. the architect hbsag qualitative ii confirmatory assay is a chemiluminescent microparticle immunoassay (cmia) for the confirmation of the presence of hepatitis b surface antigen (hbsag) in human serum and plasma including specimens collected up to 24 hours post-mortem.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbott australasia pty ltd diagnostic division - 48355 - hepatitis c virus core antigen ivd, kit, chemiluminescent immunoassay - a chemiluminescent microparticle immunoassay for the quantitative determination of hcv ag in clinical specimens. a chemiluminescent microparticle immunoassay for the quantitative determination of hcv ag in clinical specimens.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbott australasia pty ltd diagnostic division - 48446 - hiv1/hiv2 antigen/antibody ivd, kit, chemiluminescent immunoassay - for the qualitative detection of hiv p24 antigen and antibodies to human immunodeficiency virus type 1 and/or type 2 (hiv-1/hiv-2) in clinical specimens. the architect hiv ag/ab combo assay is a chemiluminescent microparticle immunoassay (cmia) for the simultaneous qualitative detection of hiv p24 antigen and antibodies to human immunodeficiency virus type 1 and/or type 2 (hiv-1/hiv-2) in human serum or plasma including specimens collected post-mortem (non-heart-beating) on the architect analyser. performance has been established for the use of cadaveric blood specimens (specimens collected post-mortem, non-heart beating) that have been collected up to 24 hours after death.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbott australasia pty ltd diagnostic division - 48524 - human t-cell lymphotrophic virus 1 & 2 (htlv1 & htlv2) antibody ivd, kit, chemiluminescent immunoassay - a chemiluminescent assay for the qualitative detection of htlv-i and htlv-ii in human clinical specimens. the architect rhtlv-i/ii assay is a chemiluminescent microparticle immunoassay (cmia) for the qualitative detection of antibodies to htlv-i and htlv-ii in human serum and plasma including specimens collected post-mortem (non-heart-beating) on the architect analyser. performance has been established for the use of cadaveric blood specimens (specimens collected post-mortem, non-heart beating) that have been collected up to 24 hours after death.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbott australasia pty ltd diagnostic division - ct869 - clinical chemistry autoimmune ivds - for the determination of autoimmune levels in human clinical specimens

Australia - English - Department of Health (Therapeutic Goods Administration)

abbott australasia pty ltd diagnostic division - ct869 - clinical chemistry autoimmune ivds - for the qualitative and/or quantitative determination of autoimmune markers in a clinical specimen